Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.1 (
protein kinase
)
81,284
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Selective
protein kinase
inhibitors have only been developed against a small number of kinase targets. Here we demonstrate that "high-throughput kinase profiling" is an efficient method for the discovery of lead compounds for established as well as unexplored kinase targets. We screened a library of 118 compounds constituting two distinct scaffolds (furan-thiazolidinediones and pyrimido-diazepines) against a panel of 353 kinases. A distinct kinase selectivity profile was observed for each scaffold. Selective inhibitors were identified with submicromolar cellular activity against PIM1, ERK5, ACK1, MPS1, PLK1-3, and Aurora A,B kinases. In addition, we identified potent inhibitors for so far unexplored kinases such as
DRAK1
,
HIPK2
, and DCAMKL1 that await further evaluation. This inhibitor-centric approach permits comprehensive assessment of a scaffold of interest and represents an efficient and general strategy for identifying new selective kinase inhibitors.
...
PMID:High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. 2180 8
Death associated
protein kinase
(DAPK)-related apoptosis-inducing protein kinase (DRAK)-1 is a positive apoptosis regulator. However, the molecular mechanisms underlying the
DRAK1
-mediated apoptotic pathway remain unclear. In this study, we demonstrated the intracellular localization and binding partners of
DRAK1
. In human osteosarcoma cell line U2OS cells,
DRAK1
was mainly localized in the nucleus and translocated outside the nucleus through Ser
395
phosphorylation by protein kinase C. In the nucleus,
DRAK1
associated with tumor suppressor p53 and positively regulated p53 transcriptional activity in response to DNA-damaging agent cisplatin. On the other hand,
DRAK1
interacted with the mitochondrial inner-membrane protein, adenine nucleotide translocase (ANT)-2, an anti-apoptotic oncoprotein, outside the nucleus. These findings suggest that
DRAK1
translocates in response to stimuli and induces apoptosis through its interaction with specific binding partners, p53 and/or ANT2.
...
PMID:Intracellular localization and binding partners of death associated protein kinase-related apoptosis-inducing protein kinase 1. 2939 38